Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBITDA: 2016-2024

Historic EBITDA for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$69.4 million.

  • Akebia Therapeutics' EBITDA rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • Per Akebia Therapeutics' latest filing, its EBITDA stood at -$69.4 million for FY2024, which was down 33.67% from -$51.9 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' EBITDA ranged from a high of -$51.9 million in FY2023 and a low of -$384.8 million during FY2020.
  • Moreover, its 3-year median value for EBITDA was -$69.4 million (2024), whereas its average is -$71.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 37.73% in 2020, then surged by 66.59% in 2022.
  • Akebia Therapeutics' EBITDA (Yearly) stood at -$384.8 million in 2020, then rose by 26.71% to -$282.0 million in 2021, then spiked by 66.59% to -$94.2 million in 2022, then spiked by 44.89% to -$51.9 million in 2023, then slumped by 33.67% to -$69.4 million in 2024.